Lv51
1480 积分 2024-10-25 加入
Nonoperative Management of Mismatch Repair–Deficient Tumors
7小时前
已完结
Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine
14天前
已完结
Harnessing the biology of regulatory T cells to treat disease
14天前
已完结
TH1 and TH2 cells: a historical perspective
30天前
已完结
What is on the Horizon Beyond Platinum and Immunotherapy for Patients With Advanced Non–Small Cell Lung Cancer Without Actionable Genomic Aberrations?
30天前
已关闭
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
1个月前
已完结
Gastric cancer
1个月前
已完结
Phase III Evaluation of Treatment Combinations in Three-Arm Trials
2个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2个月前
已完结
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
